Vyome
HIND2.1401.38% ( -0.030 )
Vyome (HIND)
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the Un...
- Open
- 2.170
- High
- 2.270
- Low
- 2.125
- Prev. Close
- 2.170
- Volume
- 10.17K
- Turnover
- 22.05K
- Avg Price
- 2.168
- Bid/Ask Ratio
- --
- Amplitude
- 6.68%
- 52wk High
- 16.200
- Volume Ratio
- 0.98
- Turnover Ratio
- 0.28%
Vyome Analyst Rating
View MoreForecast & Rating
May 29, 2026Price forecast
$11.50437.38%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 1 at 07:02 AM
Vyome wins China patent for besifloxacin gel in inflammatory acne
- Earnings Watch · May 29 at 07:44 AM
Vyome | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K
- Earnings Watch · May 12 at 03:05 PM
Vyome | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K
- Earnings Watch · Apr 24 at 05:33 AM
Vyome | 10-K: FY2025 Revenue Beats Estimate at USD 319.71 K
- Tip Ranks · Apr 23 at 12:35 PM
Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market
- benzinga_article · Mar 26 at 04:05 PM
12 Health Care Stocks Moving In Thursday's After-Market Session
